705287-60-1

Stamulumab (MYO-029; ip; 1-10 mg/kg/week for 12 weeks) increases skeletal muscle mass in vivo in a concentration-dependent manner in SCID mice. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia^[1].
Stamulumab (i.v.; 1, 5, 20, 100 mg/kg/week for 4 weeks) has a central clearance (CL) of 0.25 mL/h/kg in C57/SCID mice^[1].
Pharmacokinetic Parameters of Stamulumab (MYO-029)^[1].